Cambridge UK, 31st October 2011 - Antitope Ltd., UK ("Antitope") today announced a research agreement with Kolltan Pharmaceuticals, Inc. ("Kolltan") for the generation of therapeutic monoclonal antibodies for the treatment of cancer. Under the agreement, Antitope will apply its proprietary Composite Human Antibody™ technology for the generation of humanized antibodies.
"We are delighted to be working with Kolltan who we recognize as leaders in developing novel antibody-based cancer therapies by targeting receptor tyrosine kinases," said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope. "We are excited about the prospects for Kolltan’s therapeutic antibodies and this collaboration underlies the continuing success of our Composite Human Antibody™ technology."
"Kolltan is pleased to mark an important milestone in its development of novel therapeutic antibodies by collaborating with Antitope in the application of its proprietary humanization procedures,” commented Michael Schmertzler, Chief Executive Officer of Kolltan. “We have been impressed by Antitope’s understanding of Kolltan's commercial needs and look forward to developing the molecule they will provide to us."
Antitope Ltd. is a privately-held Cambridge UK-based biotechnology company specializing in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. Antitope’s proprietary EpiScreen™ technology enables preclinical analysis of the potential for immunogenicity of therapeutic antibodies and proteins. Antitope's proprietary Composite Human Antibody™ technology results in the generation of humanized antibodies devoid of T cell epitopes. Antitope has established multiple commercial relationships with leading biotechnology and pharmaceutical companies worldwide. For further information on Antitope visit www.antitope.co.uk or contact:
Dr Neil Butt
Business Development Director, Antitope Ltd.
Tel: +44 (0)1223 496190
About Kolltan Pharmaceuticals
Kolltan Pharmaceuticals, Inc., a privately-held biopharmaceutical company based in New Haven, Connecticut, is developing multiple antibody-based products for the treatment of cancer. These products are based on novel proprietary insights relating to receptor tyrosine kinases (RTKs) arising from the labs of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine. Kolltan was founded in 2007 and has raised $50 million to date. For further information on Kolltan, visit www.kolltan.com